BOX 1

Sample checklist for prepregnancy management of persons with HIV

- Campro Chochan is proprogramo, management of percent minimum.		
Checklist for Prepregnancy Management of Persons With HIV This checklist is a sample and should be modified as needed to fit local circumstances Discuss ways to safely become pregnant. Ensure an undetectable HIV viral load prior to attempting pregnancy. Ensure combined antiretroviral therapy (cART) agents are appropriate for use during pregnancy. Laboratory testing: HIV viral load CD4 T-lymphocyte cell count Antiretroviral drug resistance (genotype) panel G6PD and HLA-B* 5701 Toxoplasmosis immunity Hepatitis B surface antigen, hepatitis B surface antibody Hepatitis A total antibody Hepatitis C antibody Tuberculosis screening (PPD skin test or quantiferon) Ensure vaccines are up to date (pneumococcal, hepatitis B, hepatitis A, flu, MMR, varicella, HPV, tDAP). Consult CDC for HIV-specific vaccine recommendations: cdc.gov/vaccines/adults/rec-vac/health-conditions/hiv.html Optimize comorbidities (smoking cessation, treatment for opiate use disorders, treatment for viral hepatitis [B or C], management of diabetes, hypertension, cervical HPV). Discuss disclosure of patient's HIV status to partner(s). Offer partner(s) testing and referral to infectious disease specialist if indicated. Discuss PrEP. Ensure partner's vaccines are up to date.		
Version: September 23, 2020.		
CD4, T-lymphocyte cluster of differentiation 4; CDC, Centers for Disease Control and Prevention; G6PD, glucose-6-phosphate dehydrogenase; HPV, human papillomavirus, MMR, measles, mumps, rubella vaccine; PPD, purified protein derivative; PrEP, preexposure prophylaxis; tDAP, tetanus, diphtheria, acellular pertussis vaccine.		
Gibson, SMFM Special Statement: Updated checklists for pregnancy management in persons with human immunodeficiency virus. Am I Obstet Gynecol 2020.		

BOX 2

Sample checklist for antepartum management of gravidas with HIV

Checklist for Antepartum Management of Gravidas With HIV This checklist is a sample and should be modified as needed to fit local circumstances. First Prenatal Visit □ Laboratory testing: ☐ Order any tests listed in prepregnancy checklist that are not already completed. ☐ Update: ☐ HIV viral load ☐ CD4 T-lymphocyte cell count ☐ Begin cART regimen that contains three active medications based on perinatal guidelines recommendations and/or consult with specialist. ☐ Do not wait for genotype results to start treatment. ☐ If HLA-B* 5701-positive, do not use abacavir. ☐ If G6PD deficiency is present, do not use trimethoprim/sulfamethoxazole for *Pneumocystis jirovecii* prophylaxis or treatment. ☐ If currently on effective cART, continue the same treatment during pregnancy unless contraindicated. ☐ If CD4 T-lymphocyte count <200 copies/mL, begin prophylaxis against opportunistic infections. ☐ Consult resources to be sure that medication regimen is up to date and consistent with national guidelines: ☐ aidsinfo.nih.gov (Perinatal Guidelines) ☐ Perinatal HIV hotline: nccc.ucsf.edu/clinician-consultation 1-888-448-8765 ☐ Update vaccinates as needed per CDC guidance: cdc.gov/vaccines/adults/rec-vac/health-conditions/hiv.html **First and Second Trimesters** ☐ Recheck CD4 T-lymphocyte cell count every 3 months. ☐ Every 6 months for patients with undetectable viral load and CD4 count >200 copies/mL Recheck viral load monthly until RNA levels are undetectable, then every 1-3 months thereafter. ☐ Recheck viral load 2-4 weeks after initiating (or changing) cART. ☐ If failure of viral suppression is found: ☐ Assess adherence. ☐ Consult an HIV treatment expert. ☐ Assess adherence and tolerance to cART at every patient visit. ☐ Address nausea or other barriers to adherence. ☐ Give vaccines if needed (pneumococcal, hepatitis A and B, influenza). ☐ If on protease inhibitor-based regimen, consider early glucose screening. **Third Trimester** ☐ Repeat screening for syphilis, gonorrhea, and chlamydia at 28-34 weeks. ☐ Reassess viral load at 34-36 weeks for delivery planning. ☐ If viral load is not suppressed, assess adherence and viral resistance. ☐ Make a postpartum plan for cART. ☐ Determine plan for contraception after delivery. ☐ Discuss infant plan of care and availability of pediatric infectious disease team for prophylaxis. ☐ Make delivery plan including whether zidovudine will be used and route of delivery. ☐ If viral load is ≥1000 copies/mL at 37-38 weeks, schedule cesarean delivery at 38 weeks. Version: September 23, 2020. cART, combined antiretroviral therapy; CD4 T-lymphocyte, cluster of differentiation 4; CDC, Centers for Disease Control and Prevention; G6PD, glucose-6-phosphate dehydrogenase.

Gibson. SMFM Special Statement: Updated checklists for pregnancy management in persons with HIV. Am J Obstet Gynecol 2020.

BOX 3

Sample checklist for intrapartum and postpartum management of persons with HIV

Checklist for Intrapartum and Postpartum Management of Persons With HIV

This checklist is a sample and should be modified as needed to fit local circumstances.

Lai	Labor of Freoperatively for Oesarean		
	Treat with zidovudine (ZDV) for at least 3 hours prior to delivery [1-hour intravenous loading dose (2 mg/kg), followed		
	by continuous infusion (1 mg/kg/hr) until delivery] if viral load ≥1000 copies/ml (treatment can be considered if viral		
	load is <1000 copies/ml).		
	Avoid scalp electrodes or internal fetal monitors.		
	Ensure appropriate staff personal protective equipment is available and worn by all staff.		
	Continue cART regimen.		

Immediately After Delivery

	Establish pathway for neonatal treatment within 12 hours of delivery.		
	Avoid use of methergine or other ergotamines with protease inhibitors or cobicistat to avoid exaggerated vaso-		
	constrictive responses.		
	Continue cART regimen.		
Postpartum			
	Support formula feeding.		
	Support neonatal follow-up medication and testing plan.		

Ensure reliable contraception with condoms.Discuss PrEP.

☐ Continue cART regimen.

☐ Ensure cervical cytology (Pap test) and HPV screening are up to date; refer to colposcopy if needed.

☐ Ensure transition to long-term follow-up with infectious disease specialist.

☐ Ensure transition to long-term follow-up with primary care provider.

Version: September 23, 2020.

cART, combined antiretroviral therapy; HPV, human papillomavirus; Pap, Papanicolaou; PrEP, preexposure prophylaxis; ZDV, zidovudine.

Gibson. SMFM Special Statement: Updated checklists for pregnancy management in persons with HIV. Am J Obstet Gynecol 2020.